Can Stem Cells Help Treat Neuropathy? The Current Research

Stem cell therapies show genuine promise for several forms of neuropathy, but the research remains largely in animal models and small early-phase human trials. No stem cell treatment for neuropathy has received regulatory approval as a standard therapy. What exists so far is a growing body of preclinical evidence, a handful of encouraging pilot studies in people, and one more established application in autoimmune nerve disease. The gap between “promising in rats” and “available at your neurologist’s office” is real, and understanding where the science actually stands matters if you are living with nerve damage and weighing your options.

Why Nerve Damage Is So Difficult to Reverse

Peripheral nerves can regenerate, at least in theory. Unlike the brain and spinal cord, peripheral nerve fibers have some capacity to regrow after injury. In practice, though, meaningful recovery is often limited. When a nerve is damaged by diabetes, chemotherapy, trauma, or autoimmune attack, the support cells that normally guide regrowth become less effective over time, scar tissue accumulates, and the chemical signals that direct new nerve fibers to their targets fade. The longer the damage persists, the harder it becomes for the body’s own repair machinery to restore function.

This is the problem stem cell researchers are trying to solve: not just replacing lost nerve cells, but reactivating the biological environment that makes nerve repair possible in the first place.

How Stem Cells Work on Damaged Nerves

Most people picture stem cells as blank-slate replacements that turn into new nerve cells. That does happen in some experimental settings, but it is not the primary way stem cells appear to help neuropathy. The leading mechanisms are less dramatic and more interesting.

First, many types of stem cells release growth factors that encourage existing nerve fibers to sprout and extend. Adipose-derived stem cells, for example, secrete nerve growth factors and other signaling molecules that influence surrounding cells to support nerve regeneration.² Lab experiments have shown that fluid from umbilical cord stem cell cultures promotes nerve fiber outgrowth at rates comparable to direct application of nerve growth factor itself.³ The cells do not need to physically become neurons to help; they change the neighborhood chemistry.

Second, stem cells can dial down the chronic inflammation that drives many neuropathies. Bone marrow mesenchymal stem cells injected into the spinal canal in animal models reduced key inflammatory molecules and inhibited the inflammatory signaling pathway in spinal cord immune cells.⁴ Similarly, adipose-derived stem cells engineered to carry an extra growth factor gene significantly reduced a key inflammatory marker in a nerve pain model.⁵

Third, stem cells can boost the repair of the insulating myelin sheath around nerve fibers, which is critical for conducting signals properly. In diabetic rats, bone marrow stem cells injected into leg muscles migrated to the sciatic nerve, settled near blood vessels feeding the nerve, and helped restore both the blood supply and the myelin structure of nerve fibers.⁶ Dental pulp stem cells given in two doses four weeks apart similarly improved nerve conduction and restored Schwann cell survival and myelination in diabetic animals.⁷

Diabetic Neuropathy Has the Most Evidence

Among all neuropathy types, diabetic peripheral neuropathy has attracted the most stem cell research, and the results are the most developed. A 2024 systematic review and meta-analysis of human studies found that stem cell therapies, primarily bone marrow-derived cells and umbilical cord mesenchymal stem cells delivered by intramuscular injection, produced measurable improvements across multiple outcomes. Motor and sensory nerve conduction velocities both improved, vibration perception thresholds dropped, and clinical neuropathy scores decreased. The side effects were minor: injection-site pain and swelling that resolved within days.⁸

Animal studies reinforce and extend this picture. A separate meta-analysis of preclinical diabetic neuropathy models found that stem cells improved nerve conduction velocity, muscle action potentials, and blood flow to the nerves. Interestingly, the subgroup analysis showed that dental pulp stem cells had the broadest effects across measured parameters, while bone marrow cells had particularly strong biochemical responses.⁹

One thing that makes diabetic neuropathy particularly devastating is the loss of small nerve fibers in the skin, which causes the burning, tingling, and numbness patients describe. Several studies have shown that stem cells can increase the density of these intra-epidermal nerve fibers. Transplantation of stem cells from children’s shed baby teeth into diabetic rats relieved neuropathic pain, improved nerve function, and increased both small nerve fiber density and blood supply to the muscles.¹⁰ Dental pulp stem cells transplanted into long-standing diabetic rats similarly improved nerve conduction, sensation thresholds, capillary density, and small nerve fiber counts over the long term.¹¹

Chemotherapy-Induced Neuropathy

Peripheral neuropathy caused by chemotherapy drugs is one of the most common reasons cancer survivors scale back or abandon treatment. Current options for managing it are limited, which makes stem cell research in this area particularly relevant, even though it is less advanced than the diabetic neuropathy work.

A striking mouse study found that just two nasal administrations of mesenchymal stem cells completely reversed signs of established neuropathy caused by cisplatin or paclitaxel, two widely used chemotherapy agents. The treated mice recovered from mechanical sensitivity, spontaneous pain behavior, and loss of small nerve fibers in the paw. The reversal depended on an anti-inflammatory pathway involving the molecule IL-10.¹² The nasal delivery route is worth noting because it avoids surgery and allows the cells to reach the nervous system relatively directly. Reviews of the broader literature on mesenchymal stem cells in chemotherapy-induced neuropathy conclude that these cells reduce oxidative stress, neuroinflammation, and nerve cell death, though researchers stress that more investigation is needed to clarify the exact mechanisms at work.¹³

Autoimmune Neuropathies and Bone Marrow Transplant

One corner of stem cell therapy for neuropathy is further along than the rest: hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy, known as CIDP. This is the autoimmune cousin of Guillain-Barré syndrome, where the immune system attacks the myelin coating of peripheral nerves. Standard treatments include long-term immunoglobulin infusions and immunosuppressive drugs, but a significant portion of patients eventually stop responding.

For those treatment-resistant patients, autologous hematopoietic stem cell transplant essentially reboots the immune system using the patient’s own blood-forming stem cells. More than 70 patients with refractory CIDP have undergone the procedure, and most showed improvement in both clinical symptoms and nerve conduction tests.¹⁴ Case reports describe marked improvement lasting months to years after transplant, with patients achieving treatment-free remission.¹⁵

The cost equation here is revealing. The average cost of a single transplant in one U.S. cohort was about $109,000. That sounds like a lot, but published estimates put the annual cost of ongoing immunoglobulin treatment for CIDP at over $136,000 per year. In that study, 80% of transplanted patients remained free of immunoglobulin and other immune treatments for up to five years afterward, while also showing greater clinical improvement.¹⁶ For a chronic disease requiring expensive indefinite therapy, a one-time procedure that produces lasting remission could end up far cheaper overall.

Nerve Injuries and Bioengineered Scaffolds

When a peripheral nerve is physically cut or torn, the challenge is different from the slow degeneration of diabetic or autoimmune neuropathy. Here, the gap between severed nerve ends needs to be bridged. Researchers are exploring engineered tubes called nerve conduits, sometimes seeded with stem cells, to guide nerve regrowth across these gaps.

Collagen-based nerve conduits loaded with Schwann cells or stem cells that had been coaxed to behave like Schwann cells have been tested in rat models of sciatic nerve gaps. The cells adhered well to the collagen walls, and conduits loaded with actual Schwann cells showed significantly improved nerve sprouting patterns in the stump beyond the gap.¹⁷ More advanced designs feature hundreds of microchannels within the conduit that physically guide nerve fibers while recruiting the body’s own stem cells to the injury site. In one such study, the micropatterned conduits attracted and concentrated more stem cells and neural progenitor cells than conventional designs, substantially enhancing nerve regeneration after injury.¹⁸

Exosomes and Cell-Free Approaches

One of the more practical hurdles with stem cell therapy is that living cells are finicky. They need careful storage, consistent quality, and they can trigger immune reactions. This has spurred interest in a workaround: instead of transplanting the cells themselves, harvesting the tiny packets of molecules the cells naturally release. These packets, called exosomes, carry proteins and genetic material that can influence surrounding tissue.

In a diabetic mouse model, exosomes harvested from mesenchymal stem cells lowered pain thresholds, increased nerve conduction velocity, boosted blood vessel density around nerves, increased small nerve fiber counts, and improved myelin thickness and nerve fiber diameter. The exosomes also shifted immune cells from a pro-inflammatory state to an anti-inflammatory one and suppressed inflammatory signaling molecules.¹⁹ Because exosomes can be standardized, stored more easily, and administered without the complexities of living cell transplantation, they represent a potentially more scalable approach.²⁰

Lab-Grown Schwann Cells from Reprogrammed Skin Cells

Schwann cells are the support cells that wrap around peripheral nerve fibers and produce myelin. They are essential for nerve repair, but harvesting them from a patient means sacrificing a healthy nerve. Researchers have found a way around this by reprogramming ordinary cells, often skin cells, into induced pluripotent stem cells, which can then be directed to become Schwann cells capable of producing myelin.²¹

The maturity of these lab-grown cells turns out to matter a great deal. In a rat sciatic nerve injury model, Schwann cells derived from iPSCs and treated with a maturation compound promoted nerve regeneration far more effectively than untreated, immature Schwann cells. The mature cells improved both the structural appearance of regenerating nerves and functional recovery.²² Another approach coated nerve conduits with iPSC-derived neural stem cells that differentiated into Schwann-like cells before implantation, combining the scaffold strategy with cell replacement.²³

Various stem cell types, including mesenchymal stem cells, skin precursor cells, and neural stem cells, can be nudged to function like Schwann cells, giving researchers multiple paths toward a renewable supply of these critical support cells without needing to harvest healthy nerves from patients.²⁴

How Delivery Method and Timing Affect Results

A recurring question in this field is how to get the cells where they need to go. Injecting stem cells directly into a muscle near the affected nerve is the most common route in diabetic neuropathy studies. But cells have also been injected into the spinal canal, delivered intravenously, and even administered through the nose. A systematic review of mesenchymal stem cell transplantation for nerve-injury pain found that the pain-relieving effect held regardless of the type of stem cell used, the timing of administration, or the delivery route. Interestingly, after intravenous or spinal injection, the cells migrated specifically toward the injured side’s spinal cord and nerve roots.²⁵

Tracking where transplanted cells end up has been a technical challenge. MRI-based monitoring has shown that labeled stem cells can be tracked for days to weeks after transplantation into injured nerves, and the imaging can detect signs of enhanced nerve regeneration over time.²⁶ More advanced protocols using high-field MRI and iron-particle-labeled cells have extended this window to at least four weeks, allowing researchers to confirm that transplanted cells survive and integrate into nerve grafts.²⁷

Combining Stem Cells with Rehabilitation

Transplanting cells is only part of the equation. A growing body of work in “regenerative rehabilitation” suggests that pairing stem cell treatments with physical activity or electrical stimulation amplifies the results. The logic is straightforward: exercise and stimulation provide the nerve with signals that say “this pathway is needed,” which helps direct regenerating fibers to useful targets rather than growing aimlessly.

One landmark study in peripheral nerve repair found that coupling brief electrical stimulation of the nerve with transplanted motor neuron cells produced impressive cell survival and muscle re-innervation, suggesting that the combination of cell therapy and targeted stimulation may be critical for achieving real functional recovery.²⁸ Broader reviews of the regenerative rehabilitation concept emphasize that integrating stem cell therapy with tailored rehabilitation amplifies the body’s innate repair capacity while guiding tissue remodeling toward outcomes that actually translate into function.²⁹

What Human Trials Have Shown So Far

Most of the evidence discussed above comes from animal studies. Human data for stem cell treatment of neuropathy, outside of the CIDP transplant work, remains scarce. One early-phase trial treated nine people suffering from neuropathic face and mouth pain with stem cell injections at 41 sites. At six months, more than half had reduced both their pain scores and their reliance on anti-neuropathic medications like gabapentin. Average pain scores dropped from about 7.5 out of 10 to about 4.3, and no one experienced systemic or local tissue side effects.³⁰

These numbers are encouraging, but nine patients without a control group is a very preliminary signal. The human meta-analysis in diabetic neuropathy discussed earlier is more robust, pooling data from multiple studies and confirming improvements in nerve conduction and clinical scores with minimal side effects.⁸ Still, no large randomized controlled trial has yet established stem cell therapy as a validated treatment for the common forms of peripheral neuropathy.

Unproven Clinics and What to Watch Out For

The gap between laboratory excitement and regulatory approval has created an industry of clinics marketing unproven stem cell treatments. A study of crowdfunding campaigns for stem cell procedures targeting neurological conditions found over a thousand campaigns requesting a collective $33 million, with donors contributing about $5 million. The most commonly named destinations were clinics in Panama, the United States, and Mexico.³¹

These clinics typically charge thousands to tens of thousands of dollars for injections of cells whose identity, purity, and dose are not standardized. The procedures generally have not been tested in controlled trials for the specific condition being treated. This does not automatically mean they are dangerous, but it does mean that patients are paying for something with unknown efficacy and uncertain risk. If you are considering a stem cell procedure for neuropathy, legitimate clinical trials registered with government databases are a far safer way to access experimental treatments, often at no cost. Any clinic that guarantees results or discourages you from consulting your neurologist is a red flag.

How Dental Pulp Stem Cells Emerged as an Unexpected Contender

One recurring surprise across the neuropathy literature is the performance of stem cells harvested from dental pulp, the soft tissue inside teeth. These cells, which can be obtained from extracted wisdom teeth or even children’s shed baby teeth, have shown strong results in multiple animal models of diabetic neuropathy. They improved nerve conduction, restored small fiber density in the skin, promoted Schwann cell survival, and even boosted blood supply to affected tissues. In the animal meta-analysis described earlier, dental pulp stem cells had the broadest positive effects across all measured parameters.⁹ Part of the appeal is practical: dental pulp is easy to collect from tissue that would otherwise be discarded, and the cells can be banked for future use. Whether their preclinical advantage holds up in human trials remains to be seen, but they are an active area of interest precisely because the source material is so accessible.